相关实验视频
Updated: Jul 2, 2026

12:59
Barnes Maze Testing Strategies with Small and Large Rodent Models
Published on: February 27, 2014
不同饮食限制方案对阿尔茨海默病小鼠模型认知功能和病理标记的影响:系统性审查和元分析
Lirui Sun1, Xinyi Xu1, Zihan Wang2
1School of Nursing, Hebei Medical University, Shijiazhuang, Hebei, China.
Neuroscience and biobehavioral reviews
|February 10, 2026
概括
饮食限制对阿尔茨海默病 (AD) 的治疗有希望. 卡路里限制提供了一致的好处,而其他饮食的有效性各不相同,这表明AD治疗的个性化营养.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 营养科学 营养科学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 非药物干预措施,包括饮食限制 (DR),正在为AD探索.
- 现有的研究缺乏在AD模型中对不同DR疗法进行全面比较.
研究的目的:
- 在阿尔茨海默病小鼠模型中系统地审查和元分析五种饮食限制方案的疗效.
- 为了比较卡路里限制,间歇性禁食和模仿禁食饮食对AD病理和认知的影响.
- 为阿尔茨海默病治疗策略提供精确营养框架.
主要方法:
- 对23项涉及阿尔茨海默病小鼠模型研究的系统审查和元分析.
- 各种饮食限制策略的比较:热量限制,间歇性禁食,模仿禁食的饮食等.
- 对结果的分析,包括认知功能,神经炎症和其他AD相关的生物标志物.
主要成果:
- 卡路里限制在所有研究中都显示出最一致的有益影响.
- 间歇性禁食显示出可变的疗效,在一些模型中改善记忆,但在其他模型中恶化神经炎症 (例如,5×FAD模型).
- 禁食模仿饮食在评估方案中表现出最大的效果大小.
结论:
- 饮食限制是阿尔茨海默病的可行的非药物治疗方法.
- 抗逆转移干预的有效性取决于具体的治疗方案和个体的疾病概况.
- 建议采用精准营养框架,将干预措施定制为患者特定的因素,以优化阿尔茨海默病的治疗结果.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...